Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Share-based Compensation (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Share-based Compensation for 2 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 24.92% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.8 million through Dec 2025, down 8.84% year-over-year, with the annual reading at $11.8 million for FY2025, 8.84% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.1 million at Pyxis Oncology, down from $3.1 million in the prior quarter.
  • The five-year high for Share-based Compensation was $4.3 million in Q1 2024, with the low at $2.1 million in Q4 2025.